Chronic renal allograft rejection: No response to mycophenolate mofetil

Daniel Glicklich, Bharat Gupta, Gerrilinn Schurter-Frey, Stuart M. Greenstein, Richard S. Schechner, Vivian A. Tellis

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background. Mycophenolate mofetil (MMF) has been previously shown to prevent functional deterioration in an experimental model of chronic renal allograft rejection. Methods. In this retrospective case-control study, patients with chronic rejection who were receiving cyclosporine or tacrolimus and who had MMF added to their immunosuppressive regimen were compared with patients with chronic rejection who were not receiving MMF. Patients were matched for serum creatinine levels and transplant duration at the time MMF was begun. Results. In the MMF group, the average dose of MMF was 1482 mg/day with an average duration of 19.3 months. Over 36 months, including 12 months before MMF and up to 24 months on MMF, there was no difference in serum creatinine levels between the two groups. Cyclosporine levels and dose were no different. Conclusions. In this small, retrospective, preliminary study, adding MMF to maintenance immunosuppression provided no clear benefit to renal allograft recipients with established chronic rejection. Larger prospective randomized studies are needed.

Original languageEnglish (US)
Pages (from-to)398-399
Number of pages2
JournalTransplantation
Volume66
Issue number3
StatePublished - Aug 15 1998

Fingerprint

Mycophenolic Acid
Allografts
Kidney
Cyclosporine
Creatinine
Tacrolimus
Immunosuppressive Agents
Serum
Immunosuppression
Case-Control Studies
Theoretical Models
Retrospective Studies
Maintenance
Prospective Studies
Transplants

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Glicklich, D., Gupta, B., Schurter-Frey, G., Greenstein, S. M., Schechner, R. S., & Tellis, V. A. (1998). Chronic renal allograft rejection: No response to mycophenolate mofetil. Transplantation, 66(3), 398-399.

Chronic renal allograft rejection : No response to mycophenolate mofetil. / Glicklich, Daniel; Gupta, Bharat; Schurter-Frey, Gerrilinn; Greenstein, Stuart M.; Schechner, Richard S.; Tellis, Vivian A.

In: Transplantation, Vol. 66, No. 3, 15.08.1998, p. 398-399.

Research output: Contribution to journalArticle

Glicklich, D, Gupta, B, Schurter-Frey, G, Greenstein, SM, Schechner, RS & Tellis, VA 1998, 'Chronic renal allograft rejection: No response to mycophenolate mofetil', Transplantation, vol. 66, no. 3, pp. 398-399.
Glicklich D, Gupta B, Schurter-Frey G, Greenstein SM, Schechner RS, Tellis VA. Chronic renal allograft rejection: No response to mycophenolate mofetil. Transplantation. 1998 Aug 15;66(3):398-399.
Glicklich, Daniel ; Gupta, Bharat ; Schurter-Frey, Gerrilinn ; Greenstein, Stuart M. ; Schechner, Richard S. ; Tellis, Vivian A. / Chronic renal allograft rejection : No response to mycophenolate mofetil. In: Transplantation. 1998 ; Vol. 66, No. 3. pp. 398-399.
@article{993ab2bc1c834ea58badf067b9a59c39,
title = "Chronic renal allograft rejection: No response to mycophenolate mofetil",
abstract = "Background. Mycophenolate mofetil (MMF) has been previously shown to prevent functional deterioration in an experimental model of chronic renal allograft rejection. Methods. In this retrospective case-control study, patients with chronic rejection who were receiving cyclosporine or tacrolimus and who had MMF added to their immunosuppressive regimen were compared with patients with chronic rejection who were not receiving MMF. Patients were matched for serum creatinine levels and transplant duration at the time MMF was begun. Results. In the MMF group, the average dose of MMF was 1482 mg/day with an average duration of 19.3 months. Over 36 months, including 12 months before MMF and up to 24 months on MMF, there was no difference in serum creatinine levels between the two groups. Cyclosporine levels and dose were no different. Conclusions. In this small, retrospective, preliminary study, adding MMF to maintenance immunosuppression provided no clear benefit to renal allograft recipients with established chronic rejection. Larger prospective randomized studies are needed.",
author = "Daniel Glicklich and Bharat Gupta and Gerrilinn Schurter-Frey and Greenstein, {Stuart M.} and Schechner, {Richard S.} and Tellis, {Vivian A.}",
year = "1998",
month = "8",
day = "15",
language = "English (US)",
volume = "66",
pages = "398--399",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Chronic renal allograft rejection

T2 - No response to mycophenolate mofetil

AU - Glicklich, Daniel

AU - Gupta, Bharat

AU - Schurter-Frey, Gerrilinn

AU - Greenstein, Stuart M.

AU - Schechner, Richard S.

AU - Tellis, Vivian A.

PY - 1998/8/15

Y1 - 1998/8/15

N2 - Background. Mycophenolate mofetil (MMF) has been previously shown to prevent functional deterioration in an experimental model of chronic renal allograft rejection. Methods. In this retrospective case-control study, patients with chronic rejection who were receiving cyclosporine or tacrolimus and who had MMF added to their immunosuppressive regimen were compared with patients with chronic rejection who were not receiving MMF. Patients were matched for serum creatinine levels and transplant duration at the time MMF was begun. Results. In the MMF group, the average dose of MMF was 1482 mg/day with an average duration of 19.3 months. Over 36 months, including 12 months before MMF and up to 24 months on MMF, there was no difference in serum creatinine levels between the two groups. Cyclosporine levels and dose were no different. Conclusions. In this small, retrospective, preliminary study, adding MMF to maintenance immunosuppression provided no clear benefit to renal allograft recipients with established chronic rejection. Larger prospective randomized studies are needed.

AB - Background. Mycophenolate mofetil (MMF) has been previously shown to prevent functional deterioration in an experimental model of chronic renal allograft rejection. Methods. In this retrospective case-control study, patients with chronic rejection who were receiving cyclosporine or tacrolimus and who had MMF added to their immunosuppressive regimen were compared with patients with chronic rejection who were not receiving MMF. Patients were matched for serum creatinine levels and transplant duration at the time MMF was begun. Results. In the MMF group, the average dose of MMF was 1482 mg/day with an average duration of 19.3 months. Over 36 months, including 12 months before MMF and up to 24 months on MMF, there was no difference in serum creatinine levels between the two groups. Cyclosporine levels and dose were no different. Conclusions. In this small, retrospective, preliminary study, adding MMF to maintenance immunosuppression provided no clear benefit to renal allograft recipients with established chronic rejection. Larger prospective randomized studies are needed.

UR - http://www.scopus.com/inward/record.url?scp=0032529444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032529444&partnerID=8YFLogxK

M3 - Article

C2 - 9721811

AN - SCOPUS:0032529444

VL - 66

SP - 398

EP - 399

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 3

ER -